Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis - Archive ouverte HAL Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2010

Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis

, (1) , , , , , , , , (1) , , , , ,
1
Maya Berg
  • Function : Author
Pieter van Der Veken
  • Function : Author
Jurgen Joossens
  • Function : Author
Valeria Castagna
  • Function : Author
Francesca Giannese
  • Function : Author
Paul Cos
  • Function : Author
Wim Versées
  • Function : Author
Jan Steyaert
Achiel Haemers
  • Function : Author
Massimo Degano
  • Function : Author
Louis Maes
  • Function : Author
  • PersonId : 906217
Harry P de Koning
  • Function : Author
Koen Augustyns
  • Function : Author

Abstract

In this paper, we present the biochemical and biological evaluation of N-arylmethyl-substituted iminoribitol derivatives as potential chemotherapeutic agents against trypanosomiasis. Previously, a library of 52 compounds was designed and synthesized as potent and selective inhibitors of Trypanosoma vivax inosine-ade-nosine-guanosine nucleoside hydrolase (IAG-NH). However, when the compounds were tested against bloodstream-form Trypanosoma brucei brucei, only one inhibitor, N-(9-deaza-adenin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol (UAMC-00363), displayed significant activity (mean 50% inhibitory concentration [IC 50 ] standard error, 0.49 0.31 M). Validation in an in vivo model of African trypanosomiasis showed promising results for this compound. Several experiments were performed to investigate why only UAMC-00363 showed antiparasitic activity. First, the compound library was screened against T. b. brucei IAG-NH and inosine-guanosine nucleoside hydrolase (IG-NH) to confirm the previously demonstrated inhibitory effects of the compounds on T. vivax IAG-NH. Second, to verify the uptake of these compounds by T. b. brucei, their affinities for the nucleoside P1 and nucleoside/nucleobase P2 transporters of T. b. brucei were tested. Only UAMC-00363 displayed significant affinity for the P2 transporter. It was also shown that UAMC-00363 is concentrated in the cell via at least one additional transporter, since P2 knockout mutants of T. b. brucei displayed no resistance to the compound. Consequently, no cross-resistance to the diamidine or the melaminophenyl arsenical classes of trypanocides is expected. Third, three enzymes of the purine salvage pathway of procyclic T. b. brucei (IAG-NH, IG-NH, and methylthioadenosine phosphorylase [MTAP]) were investigated using RNA interference. The findings from all these studies showed that it is probably not sufficient to target only the nucleoside hydrolase activity to block the purine salvage pathway of T. b. brucei and that, therefore, it is possible that UAMC-00363 acts on an additional target.

Dates and versions

mnhn-02047414 , version 1 (13-06-2020)

Identifiers

Cite

Maya Berg, Linda Kohl, Pieter van Der Veken, Jurgen Joossens, Valeria Castagna, et al.. Evaluation of Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2010, 54 (5), pp.1900-1908. ⟨10.1128/aac.01787-09⟩. ⟨mnhn-02047414⟩

Collections

MNHN CNRS
62 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More